J Drugs Dermatol. 2025 Aug 1;24(8):777-781. doi: 10.36849/JDD.9210.
ABSTRACT
BACKGROUND: Psoriatic arthritis (PsA) is undiagnosed in up to 41% of cases, risking irreversible joint damage if untreated. This quality improvement initiative facilitates PsA screening, assessment, and rheumatology referral to improve patient outcomes.
METHODS: Our clinical framework integrated the Psoriasis Epidemiology Screening Tool (PEST) and the 12-item Psoriatic Arthritis Impact of Disease questionnaire (PsAID-12) into the electronic medical record system in 26 dermatology clinics. Psoriasis (PsO) patients underwent PsA screening via the PEST. Those scoring ≥3 or already diagnosed with PsA1 completed the PsAID-12, which guides management. PsAID-12 score >4 indicates an unacceptable symptom state, prompting treatment changes or rheumatology referral.2 Providers received results in real-time for review.
RESULTS: Over 27 months, 7,692 PsO patients were seen by dermatology providers. Of the 6,473 PsO patients without a PsA diagnosis, 37.2% completed the PEST; 12.5% scored ≥3 and completed the PsAID-12. 75.7% of patients who took the PsAID-12 scored ≤4, indicating effective management. Of the 24.3% of patients scoring >4, 24.7% were referred to rheumatology, and 44.4% subsequently received a diagnosis of PsA. When comparing the 493 patients who took the PsAID-12 at least twice, an average baseline PsAID-12 score of 2.80 was seen compared to an average most recent score of 2.53, indicating a significant reduction (P<0.0001).
CONCLUSION: Our study demonstrates the feasibility of IDEOM’s clinical framework in optimizing PsA screening, assessment, and quality of care.
PMID:40773599 | DOI:10.36849/JDD.9210